Nivolumab/pembrolizumabMyasthenia gravis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1751卷 / 1期

关键词：

D O I：

10.1007/s40278-019-61433-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：300 / 300

相关论文

共 50 条

[1] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2018, 1694 (1) : 353 - 353
[2] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2017, 1660 (1) : 264 - 264
[3] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2021, 1846 (1) : 260 - 260
[4] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2019, 1776 (1) : 364 - 364
[5] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2021, 1873 (1) : 207 - 207
[6] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2024, 2033 (1) : 233 - 233
[7] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2017, 1658 (1) : 373 - 373
[8] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2021, 1853 (1) : 390 - 390
[9] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2019, 1764 (1) : 268 - 268
[10] PembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2021, 1878 (1) : 434 - 434

← 1 2 3 4 5 →